19:53 , May 13, 2019 |  BC Extra  |  Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
19:53 , Mar 25, 2019 |  BioCentury  |  Politics, Policy & Law

Is personalized medicine doomed worldwide if biosimilars fail in the U.S.?

Europe is way ahead of the U.S. in biosimilar approvals and establishing a sustainable competitive marketplace, and it is not clear that the U.S. can even catch up. But over-protecting the U.S. originator market may...
14:34 , Mar 14, 2019 |  BioCentury  |  Politics, Policy & Law

Love it or hate it, the myopic IPI won’t lower Medicare drug prices

The Trump administration has proposed that the U.S. pay similar prices to what companies charge in Europe, starting with drugs covered under Medicare Part B. The administration figures that pegging U.S. prices to an International...
13:42 , Feb 12, 2019 |  BC Innovations  |  Translation in Brief

Stabilizing mutant proteins

A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to...
21:31 , Dec 21, 2018 |  BioCentury  |  Product Development

China’s clinical talent gap

While regulatory changes in China have helped clear the way for rapid growth of its clinical trial infrastructure, the country’s dearth of clinical experts could hold back the expansion until new talent is up to...
19:12 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Dec. 4 and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral...
21:29 , Dec 4, 2018 |  BC Extra  |  Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Tuesday and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral to...
03:01 , Oct 13, 2018 |  BioCentury  |  Politics, Policy & Law

COI failure fallout

Jose Baselga resigned as CMO of Memorial Sloan Kettering Cancer Center after being accused of failing to disclose conflicts of interest, upsetting a hornet’s nest on his way out the door that is causing academic...
06:15 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million on Aug. 8 in its series B and C rounds. The company closed its series B round with $15 million led by...
17:49 , Aug 8, 2018 |  BC Extra  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while...